{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:40:18Z","timestamp":1787236818422,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","award":["175:1298\\u20131304"],"award-info":[{"award-number":["175:1298\\u20131304"]}],"id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ard.2025.08.006","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:48:09Z","timestamp":1758088089000},"page":"1983-1994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2602-1219","authenticated-orcid":false,"given":"Christopher T.","family":"Ritchlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2059-7866","authenticated-orcid":false,"given":"Alexa P.","family":"Kollmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koeun","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7039-2441","authenticated-orcid":false,"given":"Rattandeep","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-838X","authenticated-orcid":false,"given":"Soumya D.","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-2029","authenticated-orcid":false,"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/j.ard.2025.08.006_bib0001","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"10.1016\/j.ard.2025.08.006_bib0002","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ard.2025.08.006_bib0003","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.berh.2013.03.004","article-title":"How to interpret plain radiographs in clinical practice","volume":"27","author":"Brown","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.ard.2025.08.006_bib0004","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1136\/annrheumdis-2017-211433","article-title":"The effects of structural damage on functional disability in psoriatic arthritis","volume":"76","author":"Kerschbaumer","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ard.2025.08.006_bib0005","first-page":"725","article-title":"Musculoskeletal surgery in psoriatic arthritis","volume":"25","author":"Zangger","year":"1998","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2025.08.006_bib0006","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.08.006_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003841","article-title":"High prevalence of radiographic erosions in early, untreated PsA: results from the SpARRO cohort","volume":"10","author":"Hen","year":"2024","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2025.08.006_bib0008","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5152\/eurjrheum.2022.22035","article-title":"Psoriatic arthritis: differential features at the time of clinical presentation in a large cohort of patients with polyarthralgia","volume":"10","author":"Ruta","year":"2023","journal-title":"Eur J Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2025.08.006_bib0009","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2025.08.006_bib0010","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.08.006_bib0011","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.08.006_bib0012","series-title":"Tremfya: Package insert","year":"2025"},{"key":"10.1016\/j.ard.2025.08.006_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1532852","article-title":"Guselkumab binding to CD64+ IL-23\u2013producing myeloid cells enhances potency for neutralizing IL-23 signaling","volume":"16","author":"Sachen","year":"2025","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ard.2025.08.006_bib0014","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)","volume":"81","author":"Coates","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"10230","key":"10.1016\/j.ard.2025.08.006_bib0015","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"issue":"10230","key":"10.1016\/j.ard.2025.08.006_bib0016","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ard.2025.08.006_bib0017","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.41553","article-title":"Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-na\u00efve patients with psoriatic arthritis","volume":"73","author":"McInnes","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.08.006_bib0018","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"McInnes","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2025.08.006_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001457","article-title":"Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naive or TNF\u03b1 inhibitor-experienced","volume":"7","author":"Ritchlin","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.08.006_bib0020","series-title":"Tremfya (EMA): Package insert","year":"2022"},{"issue":"1","key":"10.1016\/j.ard.2025.08.006_bib0021","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13063-022-06945-y","article-title":"The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial","volume":"24","author":"Ritchlin","year":"2023","journal-title":"Trials"},{"issue":"8","key":"10.1016\/j.ard.2025.08.006_bib0022","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.ard.2025.08.006_bib0023","first-page":"1740","article-title":"International spondyloarthritis interobserver reliability exercise\u2013the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis","volume":"34","author":"Gladman","year":"2007","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2025.08.006_bib0024","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3899\/jrheum.130163","article-title":"Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era","volume":"40","author":"Gladman","year":"2013","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2025.08.006_bib0025","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.23568","article-title":"Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis","volume":"59","author":"Healy","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.ard.2025.08.006_bib0026","first-page":"238","article-title":"Severe psoriasis\u2013oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"issue":"1","key":"10.1016\/j.ard.2025.08.006_bib0027","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/09546634.2013.865009","article-title":"The 5-point Investigator\u2019s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials","volume":"26","author":"Langley","year":"2015","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.ard.2025.08.006_bib0028","first-page":"123","article-title":"The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis","volume":"34","author":"Cassell","year":"2007","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2025.08.006_bib0029","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ard.2025.08.006_bib0030","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"suppl 2","key":"10.1016\/j.ard.2025.08.006_bib0031","article-title":"Psoriatic arthritis imaging: a review of scoring methods","volume":"64","author":"van der Heijde","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.08.006_bib0032","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.1780350105","article-title":"Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis","volume":"35","author":"van der Heijde","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2025.08.006_bib0033","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.08.006_bib0034","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2018.0793","article-title":"Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials","volume":"154","author":"Foley","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.ard.2025.08.006_bib0035","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40744-024-00654-5","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the phase 3 KEEPsAKE 1 randomized clinical trial","volume":"11","author":"Kristensen","year":"2024","journal-title":"Rheumatol Ther"},{"issue":"4","key":"10.1016\/j.ard.2025.08.006_bib0036","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/19420862.2015.1032491","article-title":"Selective targeting of the IL23 pathway: generation and characterization of a novel high-affinity humanized anti-IL23A antibody","volume":"7","author":"Singh","year":"2015","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.ard.2025.08.006_bib0037","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/imr.13379","article-title":"Living in LALA land? Forty years of attenuating Fc effector functions","volume":"328","author":"Hale","year":"2024","journal-title":"Immunol Rev"},{"issue":"7","key":"10.1016\/j.ard.2025.08.006_bib0038","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","article-title":"Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab","volume":"141","author":"Mehta","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.ard.2025.08.006_bib0039","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","article-title":"Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II\/III clinical studies in psoriasis and psoriatic arthritis","volume":"47","author":"Strober","year":"2024","journal-title":"Drug Saf"},{"issue":"14","key":"10.1016\/j.ard.2025.08.006_bib0040","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ard.2025.08.006_bib0041","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"10.1016\/j.ard.2025.08.006_bib0042","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ard.2025.08.006_bib0043","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"10370","key":"10.1016\/j.ard.2025.08.006_bib0044","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.08.006_bib0045","article-title":"Global recruiting patterns affect placebo response rates in clinical trials of psoriatic arthritis and plaque psoriasis","author":"Kerschbaumer","year":"2025","journal-title":"Arthritis Rheumatol. Published online"},{"issue":"6","key":"10.1016\/j.ard.2025.08.006_bib0046","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1055\/a-1168-6636","article-title":"How variable is the volar subcutaneous tissue of the digits on B-mode and color Doppler ultrasound in non-psoriatic individuals and could it be included in a dactylitis score?","volume":"42","author":"Rebollo-Gim\u00e9nez","year":"2021","journal-title":"Ultraschall Med"},{"issue":"1","key":"10.1016\/j.ard.2025.08.006_bib0047","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2017.12.008","article-title":"Enthesitis: a hallmark of psoriatic arthritis","volume":"48","author":"Kaeley","year":"2018","journal-title":"Semin Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725043055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725043055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T09:18:10Z","timestamp":1779614290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725043055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0003496725043055"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.08.006","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}